Adam Feuerstein's 17 thoughts for biotech in 17

Adam Feuerstein's 17 thoughts for biotech in 17


First off, will M&A pick up after a sharp drop in deals last year? The consensus says "yes," and an uptick is seen by investors as the most important tailwind for the sector this year. "I don't need to tell you what happens if deals don't materialize."



from Biotech News